Soleno Therapeutics
SLNO
SLNO was delisted on the 15th of May, 2026.
18 hedge funds and large institutions have $15.4M invested in Soleno Therapeutics in 2019 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 4 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
10% less funds holding
Funds holding: 20 → 18 (-2)
13.65% less ownership
Funds ownership: 46.06% → 32.41% (-14%)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
62% less capital invested
Capital invested by funds: $40M → $15.4M (-$24.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
+$121K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$81K |
| 3 |
TMC
Trellus Management Company
Delray Beach,
Florida
|
+$62K |
| 4 |
Renaissance Technologies
New York
|
+$28.6K |
| 5 |
SAM
Shikiar Asset Management
New York
|
+$6.38K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$12M |
| 2 |
FI
Fosun International
Hong Kong,
China
|
-$514K |
| 3 |
LC
Lindbrook Capital
Calabasas,
California
|
-$30K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$15K |
| 5 |
BlackRock
New York
|
-$6.48K |
SLNO Hedge Fund Activity: Q3 2019 in Review
18 of the 4,575 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q3 2019, worth a combined $15.4M — down 62% from $40M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of SLNO and 2 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 7 added.
The largest buyer was Oracle Investment Management, adding an estimated $121K. The largest seller was Vivo Capital, exiting entirely with an estimated $12M sold.
- 18 institutional investors held Soleno Therapeutics (SLNO) as of Q3 2019, down from 20 in Q2 2019.
- Funds reported $15.4M of Soleno Therapeutics stock for Q3 2019, down 62% quarter-over-quarter.
- 2 funds opened new Soleno Therapeutics positions in Q3 2019 and 4 closed out, a net change of -2 holders.
- The largest Soleno Therapeutics buyer in Q3 2019 was Oracle Investment Management, an estimated $121K added.
- The largest Soleno Therapeutics seller in Q3 2019 was Vivo Capital, an estimated $12M sold.
Based on aggregated 13F filings for Q3 2019.